These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 12409654)
1. Thalidomide and immunomodulatory drugs as cancer therapy. Raje N; Anderson KC Curr Opin Oncol; 2002 Nov; 14(6):635-40. PubMed ID: 12409654 [TBL] [Abstract][Full Text] [Related]
2. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Vallet S; Witzens-Harig M; Jaeger D; Podar K Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734 [TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory drugs. Crane E; List A Cancer Invest; 2005; 23(7):625-34. PubMed ID: 16305990 [TBL] [Abstract][Full Text] [Related]
4. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Schafer PH Expert Opin Pharmacother; 2012 Jul; 13(10):1541-2. PubMed ID: 22646699 [No Abstract] [Full Text] [Related]
5. The thalidomide saga. Melchert M; List A Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076 [TBL] [Abstract][Full Text] [Related]
6. [Thalidomide: mechanisms of action and new insights in hematology]. Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258 [TBL] [Abstract][Full Text] [Related]
7. [IMiDs in hematology]. Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980 [TBL] [Abstract][Full Text] [Related]
8. Lenalidomide: the emerging role of a novel targeted agent in malignancies. Kalmadi S; Baz R; Mahindra A Drugs Today (Barc); 2007 Feb; 43(2):85-95. PubMed ID: 17353946 [TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. Richardson P; Anderson K J Clin Oncol; 2004 Aug; 22(16):3212-4. PubMed ID: 15249587 [No Abstract] [Full Text] [Related]
15. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity. Breitkreutz I; Anderson KC Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684 [TBL] [Abstract][Full Text] [Related]
16. The promise of thalidomide: evolving indications. Joglekar S; Levin M Drugs Today (Barc); 2004 Mar; 40(3):197-204. PubMed ID: 15148528 [TBL] [Abstract][Full Text] [Related]
17. Thalidomide in cancer medicine. Eleutherakis-Papaiakovou V; Bamias A; Dimopoulos MA Ann Oncol; 2004 Aug; 15(8):1151-60. PubMed ID: 15277253 [TBL] [Abstract][Full Text] [Related]
18. Immunological effects of thalidomide and its chemical and functional analogs. Dredge K; Marriott JB; Dalgleish AG Crit Rev Immunol; 2002; 22(5-6):425-37. PubMed ID: 12803319 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Raje N; Hideshima T; Anderson KC Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458 [TBL] [Abstract][Full Text] [Related]
20. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. Maier SK; Hammond JM Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]